Sensei Biotherapeutics Announces Full-Year 2025 Financial Results and Corporate Update
Sensei Biotherapeutics Reports Full-Year 2025 Results, Advances PIKTOR Following Faeth Acquisition and $200 Million Financing Sensei Biotherapeutics, has reported its financial results for the full year ended December 31, 2025, while also providing a comprehensive corporate update highlighting major strategic…
CADENCE Phase 2 Data Support WINREVAIR™ in CpcPH-HFpEF
Merck Reports Positive Phase 2 CADENCE Results for WINREVAIR in CpcPH-HFpEF, Supporting Advancement to Phase 3 Merck has announced encouraging results from its Phase 2 CADENCE clinical trial evaluating WINREVAIR™ (sotatercept-csrk) in adults diagnosed with combined post- and precapillary pulmonary…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent oHCM
Phase 3 data show significant reduction in LVOT gradient and a favorable safety profile, positioning Camzyos as a potential first targeted therapy for adolescents with oHCM Bristol Myers Squibb has reported encouraging results from the Phase 3 SCOUT-HCM trial evaluating…
Incyte Reports Positive 54-Week Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026
Incyte Reports Positive 54-Week Povorcitinib Results in Hidradenitis Suppurativa at AAD 2026 Incyte has reported encouraging long-term results from its Phase 3 STOP-HS clinical trial program, highlighting the sustained efficacy and safety of povorcitinib in treating hidradenitis suppurativa (HS). The…
Angelalign Reports 2025 Results, Global Growth Driven by Clinical Excellence
Angelalign Technology (6699.HK) Releases 2025 Results, Clinical Excellence Fuels Global Growth Angelalign Technology has reported strong financial and operational performance for the fiscal year 2025, underscoring its continued expansion in both domestic and international markets. The company achieved significant growth…
SBC Medical Reports Q4 and Full-Year 2025 Financial Results
SBC Medical Reports Strong Q4 Profit Growth Despite Full-Year Revenue Decline in 2025 SBC Medical Group Holdings Incorporated a management services organization supporting a wide network of franchise-based medical businesses, has announced its financial results for the fourth quarter and…
Universal Health Services Joins 2025 GHX Millennium Club
Recognized for Driving Digital Transformation and Advancing a More Resilient, Data-Driven Healthcare Supply Chain Universal Health Services, Inc. (UHS), headquartered in King of Prussia, Pennsylvania, continues to solidify its reputation as a leader in the healthcare industry by earning a…
Carolina Complete Health, Centene Foundation Break Ground on Affordable Housing Project
Carolina Complete Health, Centene Foundation Launch Affordable Housing Project in Northeast Winston-Salem Carolina Complete Health, in collaboration with the Centene Foundation, has taken a significant step toward improving community well-being in North Carolina through a major affordable housing initiative in…
Delaware First Health and Centene Foundation Open Grant Program Submissions
Delaware First Health, Centene Foundation Open Grant Applications Delaware First Health and the Centene Foundation have officially announced the opening of a new grant submission period aimed at supporting community-based organizations and healthcare providers across Delaware. This initiative reflects a…
Real Time Medical Systems Highlights Live Data for Clinical Standards at PALTC26
Real Time Medical Systems to Showcase Live Data Solutions for Clinical Standards and Survey Readiness at PALTC26 Real Time Medical Systems (Real Time), a recognized leader in post-acute care analytics and a KLAS-rated, HITRUST-certified organization, has announced its participation in…
Sensus Healthcare Sues SkinCure Oncology Over Contract Breach
Sensus Healthcare Initiates Legal Action Against SkinCure Oncology Over Alleged Contract Breach Sensus Healthcare,a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in…
Ivonescimab Phase III NSCLC Data to Be Showcased at ELCC 2026
Multiple Ivonescimab Data Sets from Phase III Studies to Be Highlighted at ELCC 2026 Summit Therapeutics Inc. has announced the presentation of multiple updated datasets for its investigational bispecific antibody, ivonescimab, at the European Lung Cancer Congress (ELCC) 2026, scheduled…